I-Mab (IMAB) Projected to Post Quarterly Earnings on Wednesday

Key Points

• I-Mab is set to announce its Q2 2025 earnings on Wednesday, August 27th, with analysts predicting a loss of ($0.10) per share.
• Current share price of I-Mab is $4.21, with a recent 50-day moving average at $2.68 and a 200-day average at $1.57; the stock has fluctuated between a 1-year low of $0.60 and a high of $5.90.
• Brokerages have mixed views on I-Mab, with Wall Street Zen downgrading it to a "hold" while HC Wainwright maintains a "buy" rating with a $7.00 price target.

I-Mab (NASDAQ:IMAB - Get Free Report) is projected to announce its Q2 2025 results before the market opens on Wednesday, August 20th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter. Parties may visit the the company's upcoming Q2 2025 earningresults page for the latest details on the call scheduled for Wednesday, August 20, 2025 at 7:00 AM ET.

I-Mab (NASDAQ:IMAB - Get Free Report) last released its quarterly earnings data on Wednesday, August 20th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.03. On average, analysts expect I-Mab to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

I-Mab Stock Up 8.1%

IMAB traded up $0.38 during trading hours on Friday, reaching $5.09. The company's stock had a trading volume of 3,479,488 shares, compared to its average volume of 4,672,609. The company's 50-day moving average is $2.81 and its 200-day moving average is $1.66. I-Mab has a 52 week low of $0.60 and a 52 week high of $5.90.

Institutional Inflows and Outflows

An institutional investor recently raised its position in I-Mab stock. Geode Capital Management LLC boosted its stake in I-Mab Sponsored ADR (NASDAQ:IMAB - Free Report) by 147.6% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 54,562 shares of the company's stock after purchasing an additional 32,525 shares during the quarter. Geode Capital Management LLC owned about 0.07% of I-Mab worth $132,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 38.38% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on IMAB shares. Wall Street Zen upgraded shares of I-Mab from a "hold" rating to a "buy" rating in a research note on Saturday. Needham & Company LLC increased their target price on I-Mab from $5.00 to $6.00 and gave the stock a "buy" rating in a research note on Wednesday. Finally, HC Wainwright reissued a "buy" rating and set a $7.00 price target on shares of I-Mab in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $6.50.

I-Mab Company Profile

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.